Reported Earlier, Kineta Transitions From Nasdaq To OTC Markets, Continues Focus On Strategic Alternatives
Portfolio Pulse from Benzinga Newsdesk
Kineta transitions from Nasdaq to OTC Markets, trading under 'KANT'. The company continues to explore strategic alternatives, with TuHURA Biosciences having exclusivity rights for Kineta's KVA12123 program, which is in Phase 1 study.
September 20, 2024 | 6:13 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kineta has transitioned from Nasdaq to OTC Markets, now trading under the symbol 'KANT'. The company is focusing on strategic alternatives, with TuHURA Biosciences having exclusivity rights for its KVA12123 program.
The transition from Nasdaq to OTC Markets often indicates financial or operational challenges, potentially leading to a negative short-term impact on stock price. The focus on strategic alternatives and the exclusivity agreement with TuHURA Biosciences may not immediately offset investor concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100